Androgen Receptor Inhibition Increases MHC Class I Expression and Improves Immune Response in Prostate Cancer.

ABSTRACT:

Significance

Immunotherapy options for immune cold tumors, like prostate cancer, are limited. We show that AR downregulates MHCI expression/antigen presentation and that AR inhibition improves T-cell responses and tumor control. This suggests that treatments combining AR inhibitors and checkpoint blockade may improve tumor immune surveillance and antitumor immunity in patients.

SUBMITTER: Chesner LN 

PROVIDER: S-EPMC11873725 | biostudies-literature | 2025 Mar

REPOSITORIES: biostudies-literature